Pharmaceutical
- Pharmaceutical intermediates
- Heterocyclic Compound
- OLED material intermediate
- Diphenylamine intermediates
- Nutritional Supplements
- Pharmaceutical raw materials
Human APIs Powder
- Respiratory Drugs Raw Material
- Antiviral Antibacterial
- Antipyretic Analgesics
- Antihistamine Drugs
- Antineoplastic
- Urinary System Drugs
- Endocrine System
- Other
Medicine Excipients
Veterinary raw materials
Phone: 86-29-89601602
E-mail: sales21@interlgroup.com
Add: Fengcheng 2nd Road, Weiyang District, Xi'an, Shaanxi, China
Hrk supply Baloxavir marboxil Raw materials powder
Product Overview:
Baloxavixate is an innovative CAP-dependent endonuclease inhibitor and one of the few new drugs in the world that can inhibit the proliferation of influenza virus. In June 2018, the US Food and Drug Administration (FDA) accepted the new drug marketing application for baloxavixate and granted it priority review status.
Hrk supply Baloxavir marboxil Raw materials powder Attributes
CAS:1985606-14-1
MF:C22H27ClN2O4S
MW:450.98
EINECS:251-443-3
Specification: 99% min Baloxavir marboxil powder
Sample:Baloxavir marboxil powder
Packaging:1kg/bag, 25kg/drum
Brand: Henrikang
Appearance:white
Storage: Store at -20°C
Shelf Life: 2 Years
Test Method: HPLC
Hrk supply Baloxavir marboxil Raw materials powder Details
Baloxavir marboxil powder of Usage and Synthesis.
Baloxavixate is indicated for patients ≥12 years of age with acute uncomplicated influenza within 48 hours of onset of symptoms. Limitations of use should be noted: influenza viruses vary over time and there are factors such as virus type and subtype, and changes in viral resistance and virulence of the virus once they occur may undermine the clinical efficacy of antiviral drugs, and available information on the sensitivity of locally circulating virus strains to drugs should be considered when deciding whether to take basalovir.
Baloxavixolate is a small molecule precursor drug, its mechanism of action is different from the existing antiviral therapy, it can selectively inhibit CAP-dependent endonuclease, can prevent polymerase function and influenza virus mRNA replication. Existing anti-influenza drugs work by targeting neuraminidase. Compared to these drugs, Barloxavir targets an earlier stage of the viral replication cycle.
Uses of Baloxavir marboxil.
baloxavir marboxil is a selective inhibitor of CAP-dependent endonuclease of influenza virus. The drug has shown therapeutic activity in preclinical models of influenza A and B virus infections, including strains resistant to current antiviral agents.
Baloxavixolate, approved by the FDA in 2018, is a new anti-influenza drug with a novel mechanism of action, which can selectively inhibit CAP-dependent endonucrenase and prevent polymerase function and influenza virus mRNA replication.
Valoxavir was developed by Shionoyi Pharmaceuticals and has signed an agreement with Roche, including Roche subsidiary Genentech, to jointly develop and commercialize valoxavir globally, and Shionoyi/Roche is currently conducting influenza phase 3 clinical trials of valoxavir in China.
Pharmacological action of Baloxavir marboxil.
Product Methods of Bulk Baloxavir marboxil powder.
